Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Sudeep Pharma Ltd (SUDEEPPHRM)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544619 NSE: SUDEEPPHRM Pharmaceuticals & Drugs | Small Cap | Sudeep Pharma Share Price
₹1,200.60 -11.60 (-0.96%)
As on 11-Sep'26 16:59
Sudeep Pharma Ltd (SUDEEPPHRM)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544619 NSE: SUDEEPPHRM Pharmaceuticals & Drugs | Small Cap | Sudeep Pharma Share Price
₹1,200.60 -11.60 (-0.96%)
As on 11-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹13,561 Cr.
Current Price
₹1,200.6
52-Week Low / High
₹525 / 1,376
TTM EPS
₹16.2
TTM Sales
₹676 Cr.
Book Value per Share
₹81.8
P/E Ratio
74.25
In line with its 5-year historical median
Industry PE
54.2
Price to Book (P/B)
14.68
Higher than its 5-year historical median
Price to Sales (P/S)
20.07
In line with its 5-year historical median
EV/EBITDA
51.92
In line with its 5-year historical median
Dividend Yield
0.12%
Profitability Efficiency
Return on Equity (ROE)
25.37%
Outperforms industry median
Return on Capital Employed (ROCE)
28.50%
Outperforms industry median
Return on Assets (ROA)
18.43%
Operating Profit Margin
34.7%
Net Profit Margin
27.14%
Gross Profit Margin
37.1%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
-5.11%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
16.64%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
25.63%
Asset Quality
Promoter Holding
76.15%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹913 Cr.
Equity
₹11.3 Cr.
Face Value
₹1
All Time Low / High
₹524.95 / 1376.00
Check Before You Invest
Quality
Very GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Strong
Is Sudeep Pharma Ltd a good quality company?
Sudeep Pharma Ltd is a good quality company, based on a consistently good multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Sudeep Pharma Ltd performance compare with that of its Peers?
Revenue growth of Sudeep Pharma Ltd vs industry peers?
Sudeep Pharma Ltd revenue CAGR is 24.45%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Sudeep Pharma Ltd?
Promoters hold 76.15% of the Sudeep Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Sudeep Pharma Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Sudeep Pharma Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 29.1% | 26% | 28.9% | 29.8% | 37% | 37.1% | 34.6% | 38.9% | 28.7% | 20.8% | - |
| Value Creation Index ⓘ | 1.2 | 0.9 | 1.1 | 1.2 | 1.7 | 1.8 | 1.6 | 1.9 | 1.1 | 0.5 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 50 | 58.7 | 89.1 | 123 | 218 | 345 | 404 | 344 | 357 | 339 | 364 |
| Sales YoY Gr. | - | 17.4% | 51.7% | 38.1% | 77.1% | 58.3% | 17.1% | -14.9% | 3.8% | -5.1% | - |
| Adj EPS ⓘ | 0.7 | 1 | 1.1 | 1.8 | 3.4 | 5 | 6.3 | 9.8 | 9.5 | 8.3 | 10.3 |
| YoY Gr. | - | 30.1% | 17.9% | 60.7% | 90% | 46.2% | 25% | 56.8% | -3.4% | -12.3% | - |
| BVPS (₹) ⓘ | 4.3 | 5.3 | 6.5 | 8.3 | 11.9 | 17.3 | 24.4 | 34.5 | 44 | 69.6 | 72.6 |
| Adj Net Profit ⓘ | 7.1 | 9.2 | 10.9 | 17.4 | 33.2 | 48.6 | 60.6 | 95.1 | 92.1 | 93.9 | 116 |
| Cash Flow from Ops. ⓘ | 3.7 | 13.4 | 12.9 | 9.9 | 35.8 | -5.3 | 42.3 | 59.1 | 59.2 | 96 | - |
| Debt/CF from Ops. ⓘ | 1.1 | 0.3 | 0.6 | 2 | 0.9 | -13.6 | 1.7 | 1 | 2 | 1.3 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 23.7% | 9.2% | -5.7% | -5.1% | ||||
| Adj EPS ⓘ | 31% | 19.4% | 10% | -12.3% | ||||
| BVPSⓘ | 36.3% | 42.3% | 41.8% | 58.1% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 18.7 | 19.8 | 19 | 24.2 | 33.7 | 34.2 | 29.9 | 33.3 | 24.1 | 15.4 | 14.5 |
| Op. Profit Mgn % ⓘ | 23.9 | 21.6 | 19.7 | 20.6 | 21 | 19.8 | 21.9 | 38.8 | 37.3 | 35.6 | 35.3 |
| Net Profit Mgn % ⓘ | 14.2 | 15.7 | 12.2 | 14.2 | 15.2 | 14.1 | 15 | 27.7 | 25.8 | 27.7 | 31.9 |
| Debt to Equity ⓘ | 0.1 | 0.1 | 0.1 | 0.3 | 0.3 | 0.4 | 0.3 | 0.2 | 0.3 | 0.2 | - |
| Working Cap Days ⓘ | 120 | 131 | 113 | 129 | 120 | 143 | 205 | 292 | 294 | 480 | 206 |
| Cash Conv. Cycle ⓘ | 46 | 59 | 57 | 70 | 67 | 91 | 111 | 123 | 143 | 169 | 132 |
Valuation of Sudeep Pharma - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|
| Sales | 123 | 215 | 343 | 429 | 459 | 502 | 642 |
| Operating Expenses ⓘ + | 98 | 171 | 276 | 339 | 277 | 311 | 419 |
| Operating Profit ⓘ | 25 | 44 | 67 | 90 | 182 | 191 | 223 |
| Operating Profit Margin (%) | 20.6% | 20.5% | 19.7% | 21.0% | 39.7% | 38.0% | 34.7% |
| Other Income ⓘ + | 3 | 3 | 7 | 10 | 6 | 9 | 29 |
| Interest ⓘ | 1 | 1 | 2 | 6 | 5 | 7 | 9 |
| Depreciation ⓘ | 3 | 4 | 5 | 8 | 9 | 11 | 15 |
| Profit Before Tax ⓘ | 25 | 43 | 69 | 86 | 175 | 183 | 228 |
| Tax ⓘ | 7 | 10 | 18 | 24 | 42 | 44 | 54 |
| Profit After Tax | 18 | 33 | 50 | 62 | 133 | 139 | 174 |
| PAT Margin (%) | 14.7% | 15.5% | 14.6% | 14.5% | 29.0% | 27.6% | 27.1% |
| Adjusted EPS (₹) | 1.9 | 3.4 | 5.2 | 6.4 | 13.7 | 14.3 | 15.3 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 9.80% |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 81 | 114 | 163 | 223 | 356 | 493 | 883 | ||||
| Debt + | 17 | 31 | 84 | 72 | 65 | 125 | 136 | ||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 15 | ||||
| Trade Payables | 9 | 18 | 27 | 38 | 51 | 60 | 68 | ||||
| Others Liabilities ⓘ | 24 | 50 | 70 | 86 | 42 | 38 | 72 | ||||
| Total Liabilities ⓘ | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 | ||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 60 | 68 | 137 | 158 | 180 | 189 | 337 | ||||
| CWIP ⓘ | 8 | 24 | 8 | 26 | 45 | 88 | 185 | ||||
| Investments ⓘ | 6 | 19 | 0 | 3 | 0 | 0 | 0 | ||||
| Inventories | 9 | 17 | 37 | 71 | 67 | 129 | 216 | ||||
| Trade Receivables | 30 | 55 | 107 | 94 | 145 | 185 | 228 | ||||
| Cash Equivalents | 4 | 12 | 21 | 10 | 14 | 52 | 115 | ||||
| Others Assets ⓘ | 13 | 17 | 34 | 57 | 63 | 73 | 94 | ||||
| Total Assets ⓘ | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 | ||||
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 10 | 35 | -3 | 48 | 66 | 49 | 70 |
| Cash Flow From Investing Activity ⓘ + | -22 | -40 | -38 | -50 | -49 | -79 | -331 |
| Cash Flow From Financing Activity ⓘ + | 12 | 13 | 51 | -10 | -13 | 53 | 247 |
| Net Cash Flow ⓘ | -0 | 8 | 10 | -11 | 4 | 23 | -14 |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 22.28 | 34.17 | 36.15 | 32.24 | 45.98 | 32.76 | 25.37 | |||
| ROCE (%) | 25.25 | 35.71 | 35.85 | 33.22 | 48.76 | 35.83 | 28.5 | |||
| Asset Turnover Ratio | 0.94 | 1.25 | 1.23 | 1.12 | 0.98 | 0.85 | 0.69 | |||
| PAT to CFO Conversion(x) | 0.56 | 1.06 | -0.06 | 0.77 | 0.5 | 0.35 | 0.4 | |||
| Working Capital Days | ||||||||||
| Receivable Days | 90 | 72.50 | 86.30 | 85.40 | 94.70 | 115 | 115.20 | |||
| Inventory Days | 28.20 | 22.90 | 28.70 | 45.80 | 54.70 | 68 | 96.20 | |||
| Payable Days | 69.80 | 59.30 | 63.30 | 68.30 | 100.80 | 133.40 | 106.10 | |||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Sudeep Pharma Ltd FAQs
The current trading price of Sudeep Pharma on 11-Sep-2026 16:59 is ₹1,200.6.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Sep-2026 the market cap of Sudeep Pharma stood at ₹13,560.6 Cr
The latest P/E ratio of Sudeep Pharma as of 10-Sep-2026 is 116.7.
The latest P/B ratio of Sudeep Pharma as of 10-Sep-2026 is 16.54.
The 52-week high of Sudeep Pharma is ₹1,376 and the 52-week low is ₹525.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sudeep Pharma is ₹364 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Sudeep Pharma Ltd is a good quality company.
The key valuation ratios of Sudeep Pharma Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Sudeep Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Sudeep Pharma Ltd
Sudeep Pharma was incorporated as ‘Sudeep Pharma Private Limited’ as a private limited company on December 21, 1989 in Gujarat at Ahmedabad. Thereafter, the company was converted into a public limited company and the name of the company was accordingly changed to ‘Sudeep Pharma Limited’. The company was subsequently converted back to a private limited company and the name of the company was accordingly changed from ‘Sudeep Pharma Limited’ to ‘Sudeep Pharma Private Limited’. Further, pursuant to the special resolution passed by the shareholders dated August 17, 2024 and the company was converted into a public limited company and consequently, the name of the company was changed to ‘Sudeep Pharma Limited’.
The company is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries. It is one of the largest producers of food-grade iron phosphate for infant nutrition, clinical nutrition, and the food and beverage sectors. It is one of the largest exporters of mineral ingredients for pharmaceutical, food and nutrition industries from India to global markets. It is one of few companies with certification of suitability issued by the Council of Europe (CEP) and written confirmation certification for sale of calcium carbonate as an active pharmaceutical ingredient (API) in the European Union.
It leverages its inhouse developed technologies for processes such as encapsulation, spray drying, granulation, trituration, liposomal preparations and blending in an effort to drive innovation in its operations. It has established a presence in both, domestic and international markets.
Business area of the company
The company along with its subsidiary companies is engaged in business of manufacturing of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries and is dedicated to contributing to the global healthcare ecosystem by providing excipients and specialty ingredients. It develops solutions that enhance vitality, functionality, and efficiency in consumer products.
Business verticals of the company
- Pharmaceutical, Food and Nutrition Business - The company provides mineral-based ingredients for a wide range of applications in the pharmaceutical, food, and nutrition industries. Its offering includes essential mineral salts such as calcium, zinc, iron, potassium, magnesium, sodium, simethicone and copper.
- Specialty Ingredients Business - The company develops and manufactures innovative specialty ingredients, which serve various sectors such as food, nutrition, pharmaceuticals, and health supplement. Its offering includes Micro-nutrient Premixes, Liposomal Ingredients, Encapsulated Ingredients, Spray Dried Ingredients and Granulated Ingredients.
- Triturates - The company’s Tritunova line of triturated nutrients provides a uniform micronutrient blend on a carrier substrate, ensuring consistent distribution of active nutrients when incorporated into final products.
Awards, accreditations and recognition
- 2008: ‘Certificate of Appreciation for the years 2008-09 in the Exports category of Small Scale Industries’ awarded by Pharmexcil to the company.
- 2016: ‘Appreciation for contribution as a Business Partner’ awarded by Abbott to the company.
- 2021: ‘Certificate of Membership’ awarded by PRM Industries Association to the company’s Indian material subsidiary, Sudeep Nutrition Private Limited.
- 2021: ‘Appreciation for contribution during COVID’ awarded by Abbott to the company.
- 2023: ‘Certificate of Appreciation’ awarded by the Federation of Telangana Chambers of Commerce and Industry (FTCCI), Hyderabad to the company’s Indian material subsidiary, Sudeep Nutrition Private Limited.
- 2023: ‘Excellence Award for Excellence in Innovative Ingredients Manufacturing’ awarded by ASSOCHAM to the company’s Indian material subsidiary, Sudeep Nutrition Private Limited.
- 2023: ‘Suppliers Summit 2023 Award’ awarded by Herbalife to the company’s Indian material subsidiary, Sudeep Nutrition Private Limited.
- 2023: ‘Global Indian MSME of the Year in Manufacturing’ awarded by The Economic Times to the company at ‘The Economic Times MSME Awards 2023’.
- 2023: ‘Customer Centric Business Partner’ awarded by Abbott to the company.
- 2024 ‘FRK Manufacturing Excellence Award’ awarded by Millers for Nutrition to the company’s Indian material subsidiary, Sudeep Nutrition Private Limited.
History and milestones
- 1989: Incorporation of the company.
- 2017: The company obtained USFDA certification for mineral based ingredients.
- 2020: Incorporation of the company’s subsidiary, Sudeep Pharma USA Inc.
- 2021: Incorporation of the company’s subsidiary, Sudeep Nutrition Private Limited.
- 2022: The company obtained written confirmation certification for sale of calcium carbonate as an active pharmaceutical ingredient.
- 2023: Incorporation of the company’s subsidiary, Sudeep Pharma B.V.
- 2024: Incorporation of the company’s subsidiary, Sudeep Advanced Materials Private Limited.
- 2024: The company’s subsidiary, Sudeep Nutrition Private Limited, introduced liposomal encapsulation of nutrients for enhanced absorption.
- 2025: Acquisition of the company’s step-down subsidiary, Nutrition Supplies and Services (Ireland) Limited.
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
